Midkine induced growth of ameloblastoma through MAPK and Akt pathways

Oral Oncology

Volumn 40, Issue 3, 2004, Pages 274-280

  Sandra, F ^a   Harada, H ^b   Nakamura, N ^a   Ohishi, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Akt; AM 1 cells; Ameloblastoma; MAPK; Midkine

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; DNA; MIDKINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

AMELOBLASTOMA; ARTICLE; CANCER GROWTH; CELL LINE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WART VIRUS;

EID: 1642431592     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2003.08.011     Document Type: Article

References (29)

1. Lucas R.B. Ameloblastoma. Cawson R.A., Binnie W.H., Speight P.M., Barrett A.W., Wright J.M., Thorogood P. Lucas's pathology of tumors of the oral tissues (5th ed). 1998;25-44 Churchill Livingstone, London.
2. Sandra F., Mitsuyasu T., Nakamura N., Shiratsuchi Y., Ohishi M. Immuno-histochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncol. 37:2001;193-198.
3. Sandra F., Nakamura N., Mitsuyasu T., Shiratsuchi Y., Ohishi M. Two relatively distinct patterns of Ameloblastoma: an anti-apoptotic proliferating site in the outer layer (periphery) and a pro-apoptotic differentiating site in the inner layer (center). Histopathology. 39:2001;93-98.
4. Piatelli A., Fioroni M., Santinelli A., Rubini C. Expression of proliferating cell nuclear antigen in ameloblastomas and odontogenic cysts. Oral Oncol. 34:1998;408-412.
5. Slootweg P.J. P53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J. Oral Pathol. Med. 24:1995;393-397.
6. Ong'uti M.N., Cruchley A.T., Howells G.L., Williams D.M. Ki-67 antigen in ameloblastomas: correlation with clinical and histological parameter in 54 cases from Kenya. Int. J Oral Maxillofac Surg. 26:1997;376-379.
7. Kumamoto H. Detection of apoptosis-related factors and apoptotic cells in ameloblastomas: analysis by immunohistochemistry and an in situ DNA nick end-labelling method. J. Oral Pathol. Med. 26:1997;419-425.
8. Mitsuyasu T., Harada H., Higuchi Y., Kimura K., Nakamura N., Kartsuki T.et al. Immunohistochemical demonstration of bcl-2 in ameloblastoma. J. Oral Pathol. Med. 26:1997;345-348.
9. Kumamoto H., Ooya K. Immunohistochemical analysis of bcl-2 family proteins in benign and malignant ameloblastomas. J. Oral Pathol. Med. 28:1999;343-349.
10. Kramer I.R.H., Pinborg J.J., Shear M. WHO histological typing of odontogenic tumours 2nd ed. 1992;Springer-Verlag, Berlin.
11. Mitsiadis T.A., Muramatsu T., Muramatsu H., Thesleff I. Midkine (MK), a heparin-binding growth/differentiation factor, is regulated by retinoic acid and epithelial-mesenchymal interactions in the developing mouse tooth, and affects cell proliferation and morphogenesis. J. Cell Biol. 129:1995;267-281.
12. Garver R.I., Radford D.M., Donis-Keller H., Wick M.R., Milner P.G. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer. 74:1994;1584-1590.
13. Konishi N., Nakamura M., Nakaoka S., Hiasa Y., Cho M., Uemura H.et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology. 57:1999;253-257.
14. Kato M., Maeta H., Kato S., Shinozawa T., Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod Pathol. 13:2000;1060-1065.
15. Chen R.H., Sarnecki C., Blenis J. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 12:1992;915-927.
16. Traverse S., Gomez N., Paterson H., Marshall C., Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 288:1992;351-355.
17. Brunet A., Roux D., Lenormand P., Dowd S., Keyse S., Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18:1999;664-674.
18. Mishima K., Inoue K., Hayashi Y. Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol. 38:2002;468-474.
19. Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 114:2001;2903-2910.
20. Neri L.M., Borgatti P., Capitani S., Martelli A.M. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta. 1584:2002;73-80.
21. Sandra F., Matsuki N.A., Takeuchi H., Ikebe T., Kanematsu T., Ohishi M. et al. TNF inhibited the apoptosis by activation of Akt serine/threonine kinase in the human head and neck squamous cell carcinoma. Cell Signal. 14(9):2002;771-778.
22. Sandra F., Nakamura N., Kanematsu T., Hirata M., Ohisi M. The role of MDM2 in the proliferative activity of ameloblastoma. Oral Oncol. 38:2002;153-157.
23. Harada H., Mitsuyasu T., Nakamura N., Higuchi Y., Toyoshima K., Taniguchi A.et al. Establishment of ameloblastoma cell line, AM-1. J. Oral Pathol. Med. 27:1998;207-212.
24. Nakagawara A., Milbrandt J., Muramatsu T., Deuel T.F., Zhao H., Craan A.et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 55:1995;1792-1797.
25. Ikematsu S., Yano A., Aridome K., Kikuche M., Kumai H., Nagano H.et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 83:2000;701-706.
26. Raff M.C., Barres B.A., Burne J.F., Coles H.S., Ishizaki Y., Jacobson M.D. Programmed cell death and the control of cell survival: Lessons from the nervous system. Science. 262:1993;695-700.
27. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
28. Kennedy S.G., Wagner A.J., Conzen S.D., Jordan J., Bellacosa A., Tsichlis P.N.et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11:1997;701-713.
29. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 401:1999;82-85.